A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
Clinical trial NCT06063967 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06063967
- Sponsor
- AbbVie
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-15
- Primary completion
- 2027-03-01
- Enrollment
- 289
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.